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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.024In addition to its effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the
tumor necrosis factor family of receptors, promotes smooth muscle cell proliferation and migration
and may act as a survival factor for tumor cells. We hypothesized that these cellular mechanisms
of OPG may be involved in the growth and proliferation of lymphangioleiomyomatosis (LAM) cells,
abnormal smooth muscle-like cells with mutations in one of the tuberous sclerosis complex tumor-
suppressor genes (TSC1/TSC2) that cause LAM, a multisystem disease characterized by cystic lung
destruction, lymphatic inﬁltration, and abdominal tumors. Herein, we show that OPG stimulated
proliferation of cells cultured from explanted LAM lungs, and selectively induced migration of LAM
cells identiﬁed by the loss of heterozygosity for TSC2. Consistent with these observations, cells
with TSC2 loss of heterozygosity expressed the OPG receptors, receptor activator of NF-kB ligand,
syndecan-1, and syndecan-2. LAM lung nodules showed reactivities to antibodies to tumor
necrosis factorerelated apoptosis-inducing ligand, receptor activator of NF-kB ligand,
syndecan-1, and syndecan-2. LAM lung nodules also produced OPG, as shown by expression of OPG
mRNA and colocalization of reactivities to anti-OPG and anti-gp100 (HMB45) antibodies in LAM
lung nodules. Serum OPG was signiﬁcantly higher in LAM patients than in normal volunteers.
Based on these data, it appears that OPG may have tumor-promoting roles in the pathogenesis of
lymphangioleiomyomatosis, perhaps acting as both autocrine and paracrine factors. (Am J Pathol
2013, 183: 938e950; http://dx.doi.org/10.1016/j.ajpath.2013.05.024)Supported by the Intramural Research Program, the NIH, the National
Heart, Lung, and Blood Institute, and an Oak Ridge Institute for Science
and Education senior fellowship (Y.I.).
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Cardiovascular Center, Osaka, Japan.Osteoprotegerin (OPG; TNFRSF11B), a soluble member of
the tumor necrosis factor (TNF) receptor family, is best
known as a regulator of bone metabolism that promotes bone
formation by inhibiting osteoclast development, thus pro-
tecting against osteoporosis.1,2 OPG, acting as a decoy re-
ceptor, binds to receptor activator of NF-kB ligand (RANKL),
preventing the interaction of RANKL with its receptor
RANK, resulting in the inhibition of osteoclast activation
and bone resorption. Polymorphisms in the OPG gene have
been linked to development of osteoporosis.3e6 Patients
with juvenile Paget disease, a rare inherited disease affecting
children, show increased bone turnover, leading to skeletal
deformity. Mutations in the OPG gene determine the severity
of the juvenile Paget disease phenotype,7 with the loss of the
entire gene or mutations leading to the loss of OPG structure
resulting in a severe phenotype.ogy.More recently, the role of OPG in vascular cell biological
characteristics has been studied. OPG knockout mice have
both severe osteoporosis and signiﬁcant arterial calciﬁca-
tion,8 suggesting that OPG plays a protective role against
arterial calciﬁcation in mice. OPG serum levels are as-
sociated with the severity of cardiovascular disease in
humans.9e11 OPG levels may be higher either directly,
through a proatherosclerotic effect, or indirectly, because of
an incomplete compensatory mechanism in which increases
in serum OPG levels are seen as a response to RANKL
OPG and LAMactivity.9e11 This compensatory effect may also be invoked
to explain high serum levels of OPG, sometimes seen in
subjects with osteoporosis.12
Vascular smooth muscle cells express OPG, and aortic
smooth muscle cells proliferate in response to OPG.13
OPG induced both the proliferation and migration of
pulmonary artery smooth muscle cells14 and human
microvascular endothelial cells.15 The effects of OPG on
human microvascular endothelial cells were mediated
through integrins aVb3 and aVb5 and the extracellular
signaleregulated kinase 1/2. OPG can also stimulate
monocyte migration; this effect was shown to involve
syndecans and phosphatidylinositol-3-OH kinase/Akt,
protein kinase C, and tyrosine kinases.16
OPG also has roles in tumor development and metas-
tasis.17,18 OPG can bind TNF-related apoptosis-inducing
ligand (TRAIL), blocking TRAIL’s apoptotic effects on
cancer cells.19e23 Serum OPG levels may be higher in
cancer patients compared with healthy controls, and levels
may correlate with cancer stage.24e27 Tumor growth and
metastasis are also supported by OPG’s promotion of
endothelial cell survival and angiogenesis.28,29 Interestingly,
some malignant breast cancer tumors show endothelial OPG
expression, whereas neighboring normal endothelium does
not express high levels of the protein.29
Lymphangioleiomyomatosis (LAM) cells are abnormal
neoplastic smooth muscle-like cells, with mutations in one
of two tuberous sclerosis complex tumor-suppressor genes
(TSC1 or TSC2). TSC1 (encoding hamartin) and TSC2
(tuberin) form a complex that regulates the serine/threonine
kinase, mammalian target of rapamycin.30 Mutations in
TSC1/TSC2 lead to uncontrolled mammalian target of
rapamycin activity, resulting in increased cell proliferation
and size.30 These LAM cells form nodules covered with
type II pneumocytes, with surrounding areas of cystic
destruction in the lungs of patients with LAM. In addition to
the cystic destruction of lung parenchyma, LAM, a rare
multisystem disease affecting women,31 is characterized by
lymphatic abnormalities and abdominal tumors (eg, angio-
myolipomas). LAM cells can metastasize, as LAM cells
from lung lesions and angiomyolipomas in the same patient
have the same TSC2 mutation.32 Consistent with their
migratory behavior, LAM cells have been isolated from
blood and other body ﬂuids of patients with LAM.33,34
LAM cells have characteristics of both smooth muscle
cells, such as reactivity with antibodies to smooth muscle
actin and desmin, and of melanocytes, with reactivity with
HMB45,35 an antibody recognizing gp100, a melanosomal
protein.36e38
In this study, we investigated the effect of OPG on the
neoplastic smooth muscle cell-like LAM cells. OPG
promoted proliferation of cells grown from explanted LAM
lungs and speciﬁcally induced LAM cell migration. Three
OPG receptors, RANKL, syndecan-1, and syndecan-2, were
detected on LAM cells and LAM lung nodules. Further-
more, LAM cells produced OPG, and OPG levels wereThe American Journal of Pathology - ajp.amjpathol.orgelevated in serum from patients with LAM compared with
healthy volunteers, suggesting both autocrine and paracrine
effects of OPG in LAM.
Materials and Methods
Study Population
Research was approved by the Institutional Review Board
of the National Heart, Lung, and Blood Institute, Bethesda,
MD (protocols 95-H-0186 and 96-H-0100). All participants
gave written informed consent. Patients with LAM, for
serum protein measurements, had a mean age of 50.5  1.1
years and included 71 whites, four Asians, four African
Americans, and one Hispanic. Healthy volunteers were seen
at the NIH and were screened for pulmonary health by
medical history and physical examination. The exclusion
criteria for participants in the healthy volunteer group were
as follows: aged <18 or >80 years, serum test result posi-
tive for HIV or hepatitis virus, and inability to perform
reliable pulmonary function tests. The principal investigator
(J.M.) reviewed applicants with minor health problems on
a case-by-case basis. Healthy volunteers for the serum
protein measurements had a mean age of 41.4  2.0 years
and included 20 whites, ﬁve Asians, four African Ameri-
cans, one Hispanic, and one of unknown ethnicity.
Concentrations of OPG, RANKL, and TRAIL in serum
were quantiﬁed using kits from Alpco Diagnostics (Wind-
ham, NH) and Pierce Biotechnology (Rockford, IL).
Tissue Samples and Cell Culture
Lung tissue was collected from patients with LAM under-
going transplantation, and cells were grown, as previously
described,39 in mesenchymal stem cell medium (Lonza,
Walkersville, MD). Brieﬂy, lung sections obtained at
transplant were placed on plastic dishes with mesenchymal
stem cell medium containing 0.05 U/mL penicillin, 0.05
mg/mL streptomycin, 4 mmol/L glutamine, and 10% fetal
bovine serum. When colonies of cells formed, the tissue
sections were removed and cells were allowed to grow for 3
to 7 days before trypsinization and transfer to new dishes.
This procedure resulted in a heterogeneous mixture of cells
that have functional TSC2 and those with TSC2 loss of
heterozygosity (LOH). These cultures have been previously
characterized.39e41
LOH Analysis
Kg8 or D16S3395 microsatellite markers from chromosome
16 were ampliﬁed with appropriate primer pairs [Kg8
forward (50-CTCCCAGGGTGGAGGAAGGTG-30) and
Kg8 reverse (50-Fam-GCAGGCACAGCCAGCTCCGAG-30)
or D16S3395 forward (50-CTAACCCTCAGCAGAGTTC-
TG-30) and D16S3395 reverse (50-Fam-CCTGGCAGTAAG-
TCCTGAAA-30)], and products were analyzed on a 3100939
Steagall et alGenetic Analyzer (Applied Biosystems, Carlsbad, CA). LOH
was quantiﬁed as previously described.33 Brieﬂy, the heights
of the two alleles in the sample were determined (L1 and L2),
as were the heights of the alleles of the control (N1 and N2).
QLOH is deﬁned as (L1/L2)/(N1/N2), where L1 is the dimin-
ished allele. If the sample had a QLOH score <0.6, then it had
LOH.
Deﬁnition of a LAM Cell
In this study, we are deﬁning a LAM cell as a cell with
a mutation or LOH of TSC2. Although many protein markers
have been suggested to be expressed by LAM cells, none has
been shown to be exclusive to LAM cells.36 Therefore, we
chose to use the genetic deﬁnition of TSC2 LOH to specif-
ically distinguish LAM cells. No one has reported a homo-
geneous LAM cell culture from lung; all in vitro studies
using LAM lung cell cultures were performed on heteroge-
neous mixtures that have both LAM cells (TSC2 LOH) and
non-LAM cells (TSC2 functional). The heterogeneous
mixtures of cells grown from LAM lung contain 20% to 40%
TSC2 LOH LAM cells by ﬂuorescent in situ hybridization.39
In general, these LAM cells are undetectable by PCR anal-
ysis of LOH because the altered allele of the LAM cell is
obscured by the alleles of the non-LAM cells, unless frac-
tionation or selection is performed to remove some of
the non-LAM cells. Separation of populations of cells by
ﬂuorescence-activated cell sorting (FACS) using the marker
CD44v639 has been shown to enrich for and allow detection
of LAM cells having TSC2 LOH.
Proliferation
A total of 2000 cells per well of four heterogeneous
mixtures of cells grown from four different LAM lungs,
pulmonary artery smooth muscle (PASM) cells, or normal
human ﬁbroblasts were plated in 96-well plates and incu-
bated overnight at 37C with 10, 50, or 100 ng/mL of OPG,
RANKL, or TRAIL. Cell growth was measured using
a colorimetric assay (Cell Counting Kit-8; Dojindo Molec-
ular Technologies, Inc., Gaithersburg, MD). Data were
reported as a percentage of the appropriate vehicle-
containing control, and the LAM data were the average of
the results from four mixtures of cells.
Chemotaxis Assays
Chemotaxis was assayed in 24-well plates with 8-mm pores
(Chemicon, San Diego, CA), using 1  106 cells per well.
Heterogeneous mixtures of cells were added to the upper
chamber; 10% fetal bovine serum, 100 ng/mL OPG, or
chemokine ligand (CCL) 2 was added to serum-free
medium in the bottom chamber, and cells were permitted
to migrate from the upper chamber overnight at 37C. DNA
was prepared from migrated cells (QIAamp DNA Mini Kit;
Qiagen, Valencia, CA), and LOH analysis was performed.940FACS Analysis
Approximately 1  106 cells were incubated with indicated
antibodies: ﬂuorescein isothiocyanate (FITC) mouse anti-
human CD44v6 (clone VFF-7; Invitrogen, Carlsbad, CA),
phycoerythrin mouse anti-human TRAIL (clone 75402;
R&D Systems, Minneapolis, MN), Alexa Fluor 647 rat anti-
mouse RANKL (clone IK22-5; BD Biosciences, San Jose,
CA), phycoerythrin rat anti-human syndecan-1 (clone
359103; R&D Systems), and allophycocyanin rat anti-
human syndecan-2 (clone 305515; R&D Systems). Cell
sorting was performed on a MoFlo Flow Cytometer
(Beckman Coulter, Hialeah, FL). DNA was prepared
(QIAamp DNA Mini Kit; Qiagen) from the subpopulations,
and LOH analysis was performed.OPG in Cell Supernatants
Serum-starved PASM cells and three heterogeneous
mixtures of cells from LAM lungs (each from a different
patient) (100,000 cells per well of a 6-well plate) were
incubated overnight with serum-free medium, with or
without 100 ng/mL CCL2 or 100 ng/mL TNF-a, or
complete medium, and culture supernatants were collected.
OPG concentrations in the supernatants were measured by
enzyme-linked immunosorbent assay (ELISA; Alpco
Diagnostics) and normalized with the ﬁnal number of cells
in each well. PASM cells were tested six times, as were
each of the mixtures of cells. Data are reported as
a percentage of the serum-free medium control. A LAM-
speciﬁc average was calculated.RT-PCR
Laser-capture microdissection was performed on frozen
LAM lung tissue samples. LAM cells (5000 to 7000 spots)
were collected with the VERITAS microdissection system
(Arcturus Engineering, Mountain View, CA). RNA was
prepared (Arcturus Picopure RNA Isolation Kit; Applied
Biosystems). First-strand cDNA was primed with oligo dT
and random primers (Superscript First-Strand Synthesis
System for RT-PCR; Invitrogen) and PCR ampliﬁed with
primers OPGCS (50-Hex-CTGGATTTGGAGTGGTGCA-
AGC-30) and OPGCAS (50-TGTTTCCGGAACATATG-
TTGTCGTG-30). Cells from two heterogeneous mixtures
were spun down and lysed in cell lysis buffer (Signosis,
Inc., Sunnyvale, CA). OPG gene fragments were produced
using the One Step RT-PCR Kit (Qiagen) and primers
OPGCS and OPGCAS. Products were analyzed on a 3100
Genetic Analyzer. The plots show PCR product peaks. The
186-bp peak represents OPG RNA. Ampliﬁcation of
genomic DNA would result in a peak >4000 bp because
primer pair OPGCS binds to a sequence in exon 2, whereas
OPGCAS binds to a sequence in exon 3. Ampliﬁcation of
actin was performed as a positive control.ajp.amjpathol.org - The American Journal of Pathology
OPG and LAMIHC Assays
Immunohistochemical (IHC) assays were performed on
formalin-ﬁxed, parafﬁn-embedded sections. Slides were
incubated with rabbit polyclonal antibody against OPG
(H-249; Santa Cruz Biotechnologies, Inc., Santa Cruz, CA)
overnight, then washed, incubated with biotinylated goat
anti-rabbit antibody (HRP/DAB Detection System; Spring
Bioscience, Fremont, CA), and washed again before devel-
opment with 3,30-diaminobenzidine tetrahydrochloride, and
counterstained with hematoxylin. A negative control was
treated with normal rabbit IgG instead of primary antibody.
Slides were inspected with a Nikon DXM-1200 charge-
coupled device microscope (Nikon, Inc., Melville, NY), and
results were analyzed with Nikon ACT-1 software version 2.
Fluorescent IHC Assays
Slides for ﬂuorescent IHC assays were prepared from
formalin-ﬁxed, parafﬁn-embedded or frozen LAM lung
tissue sections (10 or 20 mm thick). Normal human lung
slides were obtained from Imgenex (San Diego, CA). Dual
labeling for immunoﬂuorescence evaluated colocalization of
a monoclonal antibody reaction with OPG (labeled with
Texas Red; R&D Systems) paired with HMB45 (FITC;
Dako, Carpinteria, CA) or antibodies against either CD31
(FITC; Abcam, Cambridge, MA) or podoplanin (FITC;
R&D Systems). The characterization of OPG receptors in
LAM lung tissue was accomplished by pairing a mono-
clonal antibody to a-smooth muscle actin (a-SMA) [FITC;
Epitomics (Burlingame, CA) or Sigma (St. Louis, MO)]
with anti-RANKL, antiesyndecan-2 (monoclonal anti-
bodies), anti-TRAIL, or antiesyndecan-1 (polyclonal anti-
bodies) (all Texas Red and purchased from R&D Systems).
Slides were inspected with a Zeiss LSM 510 META laser-
scanning confocal microscope equipped with 405 diode,
argon, and helium-neon laser sources, using a Plan Neoﬂuar
40 oil objective (numerical aperture, 1.3) (Carl Zeiss
Microscopy, LLC, Thornwood, NY). Results were analyzed
using LSM Image Examiner software version 4.2 SP1
(Zeiss). Controls consisted of replacing the primary anti-
body with PBS or normal mouse, goat, or rabbit IgG and
were consistently negative.
Statistical Analysis
Two-tailed t-tests were performed using Excel (Microsoft,
Redmond,WA).Testswere considered signiﬁcant atPZ0.05.
Results
OPG Stimulates Proliferation of Cells from
a Heterogeneous Mixture from LAM Lung
To examine the possible effects of OPG on LAM lung cells,
we started by testing whether OPG could induce cellThe American Journal of Pathology - ajp.amjpathol.orgproliferation. We also tested the effects of OPG’s binding
partners, RANKL and TRAIL, on the proliferation of LAM
cell mixtures. Four heterogeneous cell cultures from four
different LAM patients, PASM cells, and normal human
ﬁbroblasts were plated in 96-well plates and incubated
overnight with 10, 50, or 100 ng/mL of OPG, RANKL, or
TRAIL, and cell growth was measured. PASM cells were
used as a control for the proliferation of the abnormal smooth
muscle-like LAM cells, whereas the normal human ﬁbro-
blasts represented a control for the non-LAM cells of the
heterogeneous cultures. Data are reported as a percentage of
the appropriate vehicle-containing control, and the LAM data
are the average of the four cell mixtures. Proliferation of cells
in the LAM mixtures was not signiﬁcantly different in
medium without or with 10% fetal bovine serum (112% 
10%) (Figure 1A), whereas complete medium signiﬁcantly
stimulated proliferation of both PASM cells (127%  2%,
P < 0.001) (Figure 1B) and normal human ﬁbroblasts
(188%  5%, P < 0.001) (Figure 1C). OPG induced
proliferation of the heterogeneous LAM cultures in a dose-
dependent manner, with the lowest concentration (10
ng/mL) inducing growth to 142%  13% of the vehicle
control (P Z 0.054), 50 ng/mL stimulating 169%  10%
growth (P Z 0.005), and 100 ng/mL stimulating 182% 
17% growth (PZ 0.017). OPG also stimulated proliferation
of PASM cells and normal human ﬁbroblasts, with the
highest two concentrations stimulating proliferation signif-
icantly over the vehicle control. The highest concentration of
RANKL (100 ng/mL) signiﬁcantly induced proliferation of
cells in the LAM mixtures by 118%  2% of its vehicle
control (P Z 0.002), whereas the lower concentrations did
not have signiﬁcant effects. RANKL did not stimulate
proliferation of PASM cells at any concentration, but
signiﬁcantly stimulated proliferation of normal human
ﬁbroblasts at all three concentrations. TRAIL did not stim-
ulate proliferation of the cells of the LAM mixtures or
normal human ﬁbroblasts at any concentration, but signiﬁ-
cantly stimulated proliferation of PASM cells at the lower
two concentrations. Because more cells in the heterogeneous
cultures are non-LAM than LAM cells, the proliferative
response to OPG may be due primarily to the non-LAM
cells. Because the proliferation assay did not allow us to
identify the speciﬁc cell type responding to OPG, we next
examined which cells in the mixtures expressed receptors
that could bind OPG and mediate its effects.
OPG Receptors
Cells in our studies were heterogeneous mixtures, with both
abnormal smooth muscle-like LAM cells and non-LAM
cells, and we identiﬁed LAM cells genetically by conﬁrming
TSC2 LOH. These mixtures have 20% to 40% LAM cells,
as determined by ﬂuorescent in situ hybridization,39 and
approximately 20% of the cells reacted with antibodies to
smooth muscle actin. The effects of OPG on LAM cells may
be mediated by OPG receptors, such as type II membrane941
Figure 1 Cell proliferation induced by OPG in mixtures of LAM cells (A),
pulmonary artery smooth muscle cells (B), and normal human ﬁbroblasts
(C). A total of 2000 cells per well were plated in 96-well plates and incu-
bated overnight in serum-free medium with 10, 50, or 100 ng/mL of OPG,
RANKL, TRAIL, or complete medium (CM), and cell growth was measured
using a colorimetric assay that produced a compound that was directly
proportional to the number of living cells. Experiments were performed
three times. Data are reported as a percentage of the appropriate vehicle-
containing control (V), and the LAM data are the average of results from
four cell lines. P values for treatment versus control are above bars. Data
are means  SEM. ***P < 0.001.
Steagall et alforms of RANKL42,43 and TRAIL,44 and heparin sulfatee
containing proteoglycans, such as syndecans.16Receptors for OPG Are Expressed by Cells from
Heterogeneous Mixtures from LAM Lungs
Cells from three heterogeneous mixtures with both LAM and
non-LAM cells from explanted lungs (each from a different
LAM patient) were reacted with antibodies against RANKL,
TRAIL, syndecan-1, and syndecan-2, in addition to anti-
bodies against CD44v6, a marker of metastasis used for LAM
cell separation,39 and subjected to FACS cell sorting942followed by TSC2 LOH analysis. All three heterogeneous
cultures reacted with antibodies to OPG receptors, with an
average of 40% 14% of cells reacting with antiesyndecan-
2, 22%  9% reacting with anti-RANKL, 13%  2%
reacting with antiesyndecan-1, 12%  3% reacting with
anti-TRAIL, and 7% 2% reacting with anti-CD44v6. After
incubation with anti-CD44v6 plus antibodies against one of
the receptors, four cell populations were detected with antie
syndecan-1 and anti-TRAIL antibodies, but only three with
anti-RANKL or antiesyndecan-2 antibodies. No cells were
CD44v6þRANKL or CD44v6þsyndecan-2 (Table 1).
Cells that expressed CD44v6 had a higher level of expres-
sion of OPG receptor, as determined by mean ﬂuorescence
intensity, than cells expressing the OPG receptor alone
(Table 1). Thus, cells within the mixtures contained OPG
receptors.
Receptors for OPG Are Expressed by TSC2 LOH Cells
DNA prepared from the sorted subpopulations of cells was
tested for TSC2 LOH (Table 1). In three different hetero-
geneous cultures, DNA from the populations of CD44v6þ
RANKLþ, CD44v6þsyndecan-1þ, and CD44v6þsyndecan-
2þ showed TSC2 LOH in several experiments (100%, 71%,
and 88% of the time, respectively). FACS using anti-TRAIL
antibody did not separate a population that consistently
showed TSC2 LOH (CD44v6þTRAILþ cells showed LOH
only 57% of the time). Therefore, LAM cells with TSC2 LOH
have the surface markers CD44v6, RANKL, syndecan-1, and
syndecan-2.
Receptors for OPG Are Expressed in LAM Lung Tissue
LAM lung tissue sections from three different patients were
reacted with antibodies to RANKL, TRAIL, syndecan-1, or
syndecan-2. Confocal imaging showed reactivity for
RANKL (Figure 2A) and TRAIL (Figure 2B) in LAM
nodules, but the reactivity was present in fewer cells than
the reactivity for syndecan-1 and syndecan-2 in the prolif-
erative areas of LAM lung tissue (Figure 2, C and D). Some
LAM lung tissue cells reactive to syndecan-1, syndecan-2,
or TRAIL were also reactive to antiea-SMA antibody,
a marker of LAM nodules. Therefore, receptors for OPG are
expressed in LAM lung nodules in vivo.
OPG Speciﬁcally Induces Migration of TSC2 LOH LAM
Cells from Heterogeneous Mixtures of Cells from LAM
lung
To determine whether TSC2 LOH LAM cells have func-
tional OPG receptors, we tested the effect of OPG on the
migration of LAM cells. Because TSC2 LOH LAM cells
migrate in response to the chemokine, CCL2,41 and OPG
induces migration of monocytes through syndecan-1,16 the
effect of OPG on LAM cell chemotaxis was examined. A
heterogeneous mixture of cells from LAM lung was placedajp.amjpathol.org - The American Journal of Pathology
Table 1 FACS Analysis of Heterogeneous Cells Grown from LAM Lung, with Percentage of Cells in Population, Mean Fluorescence Intensity




Mean ﬂuorescence intensity TSC2 analysis (%)y
CD44v6 Receptor ROH LOH
CD44v6RANKL 52  2 4.8  0.4 5.1  0.3 80 20
CD44v6RANKLþ 7  3 9.1  0.7 113.6  49.3 70 30
CD44v6þRANKL 0  0 NA NA NA NA
CD44v6þRANKLþ 5  1 141.4  34.5 350.2  17.8 0 100
CD44v6syndecan-1 60  3 5.8  0.1 3.2  0.1 89 11
CD44v6syndecan-1þ 5  1 5.1  0.5 39.1  4.2 56 44
CD44v6þsyndecan-1 3  2 80.4  6.9 3.7  0.1 33 67
CD44v6þsyndecan-1þ 3  1 209.4  97.3 193.9  115.3 29 71
CD44v6syndecan-2 37  6 4.8  0.8 3.9  0.3 100 0
CD44v6syndecan-2þ 18  6 7.8  0.8 48.1  4.8 67 33
CD44v6þsyndecan-2 0  0 NA NA NA NA
CD44v6þsyndecan-2þ 5  1 91.6  7.5 92.1  13.4 13 88
CD44v6TRAIL 68  4 5.8  0.1 2.9  0.2 100 0
CD44v6TRAILþ 2  1 7.2  0.2 32.1  0.3 44 56
CD44v6þTRAIL 2  0 87.2  20.0 3.4  0.1 43 57
CD44v6þTRAILþ 4  1 108.9  13.4 81.5  24.5 43 57
*Data are means  SEM of values from three heterogeneous cell mixtures grown from LAM lungs from three different patients, each assayed at least three
times. The four cell populations do not total 100% because speciﬁc gates were drawn encompassing each population relative to negative controls.
yData are percentage of times DNA isolated from the sorted population showed ROH or LOH. Experiments were performed on three heterogeneous cell
mixtures grown from LAM lungs from three patients, at least three times each.
NA, not applicable; ROH, retention of heterozygosity.
OPG and LAMin the upper chamber, 100 ng/mL OPG or CCL2 or 10%
fetal bovine serum was added to serum-free medium in the
bottom chamber, and cells were allowed to migrate from the
upper chamber overnight. Those cells that migrated were
collected, and DNA was prepared. As shown by the pres-
ence of TSC2 LOH in the DNA of migrated cells (Figure 3),
OPG or CCL2 stimulated migration of TSC2 LOH LAM
cells from the heterogeneous mixture. Serum-free medium
and 10% fetal bovine serum did not selectively stimulate
chemotaxis of cells with TSC2 LOH. Thus, OPG can
selectively induce migration of TSC2 LOH LAM cells.
Sources of OPG
Endothelial and vascular smooth muscle cells are major
sources of circulating OPG.18 Because LAM cells and
smooth muscle cells express some genes in common, we
investigated OPG expression by LAM cells in three ways:
expression in heterogeneous cultures grown from LAM
lung, expression of OPG mRNA in samples isolated from
LAM lung nodules, and expression of OPG protein in LAM
tissue by IHC.
OPG Is Expressed by Heterogeneous Cultures
Containing Both LAM and Non-LAM Cells
Three mixtures of cells grown from explanted LAM lungs
and PASM cells were serum starved overnight, then incu-
bated overnight in medium, serum free or with TNF-a or
CCL2, as indicated, and supernatant was collected. OPG in
medium was quantiﬁed by ELISA, and OPG concentrationsThe American Journal of Pathology - ajp.amjpathol.orgwere normalized to the ﬁnal number of cells per well. Data
for the amount of OPG produced in complete medium or
with TNF-a or CCL2 are expressed as a percentage of
serum-free control. Heterogeneous LAM cell cultures
incubated with serum-free medium produced 2.7 times more
OPG than did PASM cells treated with serum-free medium
alone (P Z 0.009); thus, basal OPG expression was higher
in the LAM cell cultures than in PASM cells (Figure 4A).
OPG levels from the heterogeneous LAM cell cultures and
PASM cell cultures grown in both complete medium and
serum-free medium containing TNF-a were signiﬁcantly
higher than those from cells grown in serum-free medium
(Figure 4B). PASM cells incubated with complete medium
produced 1300%  310% more OPG than the serum-free
control (P Z 0.012), whereas the heterogeneous mixtures
from LAM lung incubated with complete medium produced
190%  10% more OPG than the serum-free control (P Z
0.015). Incubation with TNF-a produced 430%  80%
(PZ 0.008) and 190%  20% (PZ 0.031) more OPG than
the serum-free control in PASM cells and the LAM cell
mixtures, respectively. Incubation with CCL2 did not
stimulate OPG production in either LAM cell mixtures or
PASM cells. Thus, LAM cell mixtures contained cells
capable of expressing OPG; however, these data did not
demonstrate whether OPG was produced by TSC2 LOH
LAM cells.
OPG mRNA Is Detected in Microdissected LAM Nodules
To identify the cells that produced OPG, LAM nodules were
microdissected from LAM lung tissue, and RNA from the943
Figure 2 Expression of OPG receptors in LAM lung nodules demon-
strated by confocal microscopy. Tissue sections were immunoreacted with
antiea-SMA antibody (FITC, green) and anti-RANKL, anti-TRAIL, antie
syndecan-1, or antiesyndecan-2 antibodies (Texas Red, red). The four
receptors are expressed in areas of cellular proliferation (AeD). A: Cells
positive for RANKL are seen adjacent to antiea-SMA antibodyereactive
cells. Some cells within the nodule express reactivity to both antiea-SMA
antibody and anti-TRAIL (B), antiesyndecan-1 (C), or antiesyndecan-2 (D)
antibodies. E and F: The nuclei of cells were counterstained with DAPI.
Control sections (deletion of primary antibody) were negative. Scale barZ
10 mm (AeF). Frozen lung sections from three patients with LAM showed
comparable results.
Figure 3 TSC2 LOH in cells that migrated in response to OPG. Cells were
stimulated overnight with medium without serum (B) or medium with 10%
serum (C) or 100 ng/mL of OPG (D) or CCL2 (E) in the lower chamber of
a Boyden chamber. DNA was prepared from cells that migrated, and PCR was
performed to quantify chromosome 16 marker D16S3395. QLOH values were
calculated relative to peak heights in samples ampliﬁed from the blood (A,
control) of the patient who was the source of the heterogeneous mixtures
of cells grown from LAM lung. A sample with a QLOH score of <0.6 was
categorized as having LOH. Experiments were performed with two different
heterogeneous mixtures of cells grown from LAM lungs (from two different
patients) at least two times each. OPG and CCL2 each selectively stimulated
migration of cells with TSC2 LOH. AU, arbitrary unit.
Steagall et alnodules and from heterogeneous LAM cell mixtures was
prepared for RT-PCR. Products were analyzed on a 3100
Genetic Analyzer. OPG RNA was ampliﬁed from a LAM
cell mixture (Figure 5C). Although the positive control,
actin, could be ampliﬁed from four of the microdissected
samples (data not shown), two of four samples expressed
OPG RNA (Figure 5, DeG), suggesting that OPG was
expressed by some LAM nodules.
OPG and gp100 Are Co-Expressed by Cells in LAM
Nodules
IHC assays were used to investigate further OPG production
by LAM cells. An IHC reaction with anti-OPG antibodies
was seen in LAM nodules of explanted LAM lungs944(Figure 6, AeC). We found both cytoplasmic and membra-
nous reaction for OPG in LAM cells (Figure 6, A and B) and
vessel walls (Figure 6C). Immunoﬂuorescent microscopy of
explanted LAM lung tissue from six patients showed OPG in
endothelial cells lining vascular structures and in alveolar
cells. OPG is more concentrated in the vascular structures,
resulting in a strong signal, compared with the parenchyma,
where the reactivity of OPG appears to be more diffuse
(Figure 6D). In normal human lung, OPG was detected in
cells lining vascular structures, but was not detected in the
alveolar structures (Figure 6, J and K). Reaction with anti-
OPG and anti-CD31 (a marker for vascular endothelial
cells) antibodies was detected in the cytoplasm of the same
vascular endothelial cells (Figure 6, E and F). It is not clear
whether the parenchymal cells react with both the anti-OPG
and anti-CD31 antibodies, because the reactivity for anti-
CD31 was much stronger in these areas than the weaker
reactivity for OPG and may have overwhelmed the OPG
signal. OPG was not detected in the lymphatic structures that
traverse LAM nodules, using podoplanin as a lymphatic
vessel marker. Reactivity with both anti-podoplanin and anti-
OPG antibodies was seen, but in distinct cells (Figure 6G).ajp.amjpathol.org - The American Journal of Pathology
Figure 4 OPG production by PASM cells and heterogeneous mixtures of
cells grown from LAM lung. Serum-starved PASM cells and three different
heterogeneous mixtures of cells grown from LAM lung from three different
patients (100,000 cells per well of a 6-well plate) were incubated for 24
hours in serum-free medium (SF), with or without 100 ng/mL CCL2 or 100
ng/mL TNF-a, or complete medium (CM), and culture supernatants were
collected for quantiﬁcation of OPG concentrations by ELISA. PASM cells
were tested six times, as was each of the heterogeneous mixtures of cells
grown from LAM lung. LAM data are reported as a LAM cell average. Data for
proliferation stimulated by complete medium or with TNF-a or CCL2 are
percentage of serum-free medium control and were normalized to the ﬁnal
number of cells per well. P values for treatment versus control are above
bars. A: Amount of OPG per cell expressed by PASM and LAM cells incubated
in SF medium. B: OPG production in PASM and LAM cells incubated with
CCL2- or TNF-aecontaining medium or complete medium expressed as
a percentage of the SF control.
Figure 5 OPG mRNA in laser-capture microdissected LAM nodules. OPG
RNA was ampliﬁed by RT-PCR and analyzed on a 3100 Genetic Analyzer. The
186-bp peak (arrowhead) represents OPG RNA. Ampliﬁcation of genomic
DNA would result in a peak >4000 bp because primer OPGCS is from exon 2
and OPGCAS is from exon 3. Representative ampliﬁcation results from no
DNA control (A), no reverse transcriptase control (using the RNA from the
LAM cell mixture used in C) (B), RNA from a LAM cell mixture (C), and RNA
from microdissected LAM nodules (DeG). RNA isolated from a second LAM
cell mixture showed similar results to B and C (data not shown). Actin was
a positive control for the ampliﬁcation reactions in DeG (data not shown).
AU, arbitrary unit.
OPG and LAMLAM cells that reacted with the monoclonal antibody,
HMB45, which recognizes gp100, a melanosomal LAM cell
marker,35 reacted with anti-OPG antibodies (Figure 6, H and
I). Although a small subset of HMB45-positive cells did not
react with anti-OPG antibodies, incubation with antibodies
against both proteins revealed their profuse colocalization in
the cytoplasm of cells in LAM nodules. These data suggest
that production of OPG in LAM may be both paracrine and
autocrine, with OPG released by vascular structures within
LAM lung tissue and by the LAM cells themselves.
Concentrations of Serum OPG Are Signiﬁcantly Higher
in LAM Patients than Healthy Volunteers
OPG concentrations in serum from LAM patients and
healthy volunteers were quantiﬁed by ELISA. OPGThe American Journal of Pathology - ajp.amjpathol.orgconcentrations in serum from LAM patients were signiﬁ-
cantly higher than those from healthy volunteers [means 
SEM, 6.2  0.3 pmol/L (80 patients) versus 3.8 0.3 pmol/L
(34 healthy volunteers); P < 0.001].
As had been previously reported in healthy individuals,45
the concentration of OPG in serum increased signiﬁcantly
with age in LAM patients (P Z 0.004) and in healthy
volunteers (PZ 0.028). Even after adjustment for age, OPG
concentrations in serum were signiﬁcantly higher in LAM
patients than in healthy volunteers (P Z 0.003).
Because RANKL and TRAIL interact with OPG,18 we
measured RANKL and TRAIL concentrations in serum
by ELISA. TRAIL [557  27 pg/mL (78 patients) versus945
Figure 6 OPG in LAM lung lesions. A and B: Reaction with antibodies against OPG in LAM lung nodules in sections of explanted LAM lungs. C: Reactions in
cells lining vessels. Original magniﬁcations: 40 (A); 400 (B); 200 (C). The arrow indicates anti-OPG reactivity in alveolar structures (A). Anti-OPG
reactivity in LAM cells and alveolar macrophages (B). The arrowhead indicates a vascular structure, whereas the arrow indicates a LAM nodule (C). D: Confocal
ﬂuorescence imaging of lung sections. Strong positive reactivity to anti-OPG antibody (Texas Red, red) is localized to the lining of vascular structures, with
weaker reactivity in cells throughout the parenchyma. E: CD31 (FITC, green)e and OPG (Texas Red, red)epositive cells are seen in a vascular structure of a LAM
lung section. F: Higher magniﬁcation of another LAM tissue section revealed cells with reaction to antibodies against both OPG and CD31 within the same
vascular endothelial cells (merge, yellow) lining a vessel. G: Reaction with antibodies against OPG and podoplanin (FITC, green) is evident in a LAM lung
section, without, however, colocalization of immunoreactivities within the same cell. H: HMB45 (FITC, green)e and OPG (Texas Red, red)epositive cells in
a proliferative region of a LAM lung. I: Higher magniﬁcation of a tissue section demonstrated positive reactivity to HMB45 and an antibody to OPG within the
same cell (merge, yellow), suggesting that LAM cells express OPG. J: Cells immunopositive for OPG (Texas Red, red) line vascular structures in normal lung
tissue. K: No reaction to OPG is observed in normal lung alveolar cells, in contrast to the diffuse expression of OPG in LAM lung tissue. L: Control staining of
normal human lung using IgG mouse control. The nuclei of cells were counterstained with DAPI (blue). Results were similar in at least three different samples
for each pair of antibodies. LAM lung sections are from different patients (D, E, G, and H). Scale bar Z 20 mm (DeL).
Steagall et al507  26 pg/mL (35 healthy volunteers)] and RANKL
[0.16  0.01 pmol/L (80 LAM patients) versus 0.16  0.05
pmol/L (36 healthy volunteers)] concentrations showed no
signiﬁcant difference in serum from LAM patients versus946healthy volunteers. Thus, only the serum levels of OPG
were found to be different between LAM patients and
healthy volunteers of the three interacting proteins, OPG,
RANKL, and TRAIL.ajp.amjpathol.org - The American Journal of Pathology
OPG and LAMSerum Concentrations of OPG and CCL2 Are Correlated
in LAM Patients
CCL2 is a chemokine that may play a role in LAM.41
Polymorphisms in the CCL2 gene were associated with
susceptibility to LAM, and CCL2 speciﬁcally induced
migration of LAM cells with TSC2 LOH.41 In a study of
healthy normal volunteers,46 CCL2 plasma levels correlated
with RANKL concentrations in men and women, whereas in
LAM patients, no association was seen between CCL2 and
RANKL or TRAIL (data not shown). CCL2 plasma levels
correlated positively with OPG in healthy women, but not in
men.46 In LAM patients, CCL2 and OPG were positively
correlated (nZ 58; P < 0.001, adjusted for age) (Figure 7),
suggesting that CCL2 and OPG might both participate in
LAM pathogenesis, perhaps through effects on migration.
Discussion
LAM is a metastatic disease. LAM cells from lung lesions
and angiomyolipomas in the same patient have the same
TSC2 mutation,32 and recurrent LAM cells of recipient
origin have been found in the donor lung of a transplanted
patient.47,48 In support of metastatic dissemination, we were
able to isolate LAM cells from body ﬂuids, including blood,
chyle, and urine.33,34 Herein, we show that LAM cell
mixtures proliferate and TSC2 LOH LAM cells migrate
selectively in response to OPG, probably via one of the OPG
receptors, membranous RANKL, syndecan-1, or syndecan-2.
LAM cells expressed OPG, and serum levels of OPG in LAM
patients were found to be signiﬁcantly higher than those in
healthy volunteers, perhaps inducing LAM cells to enter the
bloodstream. A study comparing serum OPG levels between
healthy volunteers and patients with solid tumors found no
signiﬁcant difference between the groups, but did ﬁnd a trend
of higher serum levels of OPG in patients with metastatic
disease than in those with localized tumors.24 OPG has also
been shown to be involved in the metastasis of prostate and
breast cancer cells to bone.49
OPG is expressed by both endothelial cells and by LAM
cells within the LAM cell nodules (Figure 6). Reactivity of
anti-OPG antibodies resulted in a much stronger signal in
the endothelial cells than that seen in the nodules, where mostFigure 7 Correlation of OPG and CCL2 concentrations in serum from
LAM patients (n Z 58). P < 0.001.
The American Journal of Pathology - ajp.amjpathol.orgOPG-expressing cells showed a more diffuse cytosolic
reactivity. There were, however, some cells of the LAM
nodules that showed stronger reactivity to anti-OPG anti-
bodies. Both the endothelial cells and the LAM nodules
showed reactivity with an antibody to CD31, a marker that is
mainly used to identify endothelial cells. CD31 is expressed
on hematopoietic stem cells and endothelial cells,50 but it is
also found on circulating monocytes51 and on intratumoral
macrophages.52 Although it is clear that some of the anti-
CD31 reactivity is on vascular structures, it is not known
what type of cell reacts with the anti-CD31 antibodies in the
LAM lung parenchyma. LAM cell nodules are heteroge-
neous, with LAM cells found along alveolar walls, blood
vessels, lymphatics, and bronchioles.53 Both blood and
lymphatic vessels inﬁltrate the nodules. LAM cells them-
selves can be either proliferative spindle-shaped cells or more
differentiated epithelioid cells. It has been shown that renal
angiomyolipomas from LAM patients contain smooth
muscle cells, adipose tissue, and ﬁve types of vessels.
Interestingly, four of the ﬁve types of vessels reacted with
HMB45 and showed TSC2 LOH, as did the smooth muscle
cells and adipose tissue.54 In LAM lung, we may be seeing
a LAM cell type that expresses CD31 antigen or the inﬁl-
tration of another cell type expressing CD31.
It has been proposed that the growth of LAM cells within
the nodule is regulated by soluble factors, metalloproteases,
and chemokines. LAM cells have been shown to express
receptors for angiotensin,55 erythropoietin,40 insulin-like
growth factor,56 epidermal growth factor,57 chemokines,41
and OPG (Table 1); however, the mechanisms of action of
some of these receptors have not been clearly delineated.
We show that membrane-bound syndecan-1 and syndecan-2
are present in LAM cells (Table 1) and in LAM lung tissue
(Figure 2). Syndecans are heparin sulfate proteoglycans that
are able to bind extracellular matrix proteins, such as
integrins (eg, a5b1, aVb3, and aVb5), regulating cell adhe-
sion. Syndecans are also recruiters of growth factors and
metalloproteases.58 Thus, it is tempting to speculate that the
syndecans present in LAM cells could play a critical role in
cell proliferation, migration, and anchoring during metas-
tasis, by modulating the function of growth factors and
increasing the on-site concentration of soluble factors.
RANKL and TRAIL were also present in LAM lung tissue
(Figure 2), but in fewer cells than syndecan-1 and syndecan-2.
Cells positive for RANKL also tended to be adjacent to those
reactive to antiea-SMA antibody instead of having colo-
calized reactivities of RANKL and a-SMA. Analysis of
heterogeneous mixtures of cells cultured from LAM lung
tissue indicated, however, that CD44v6þRANKLþ cells
showed TSC2 LOH in 100% of our experiments, whereas
CD44v6þTRAILþ cells had TSC2 LOH in only 57% of
experiments (Table 1). Because the cells in the LAM nodule
have not been well characterized, it is possible that LAM cells
have variable amounts of smooth muscle actin, which would
account for the presence of TSC2 LOH in vitro in RANKL-
positive cells, whereas the RANKL-positive cells in vivo947
Steagall et almay express low levels of or undetectable smooth muscle
actin. There may also be differences in the expression of
RANKL and TRAIL in the LAM lung tissue versus cultured
cells, which could account for the in vivo versus in vitro
discrepancies.
OPG is found in the Weibel-Palade bodies of endothelial
cells and is released after stimulation by proinﬂammatory
cytokines, such as TNF-a and IL-1b.59 Although not shown
to speciﬁcally induce OPG release or expression, a study
has shown that the serum levels of CCL2, an inﬂammatory
cytokine, correlate with the serum levels of OPG.46 We also
see this association in LAM patients (Figure 7). It is possible
that CCL2 stimulates OPG release in LAM patients. We
have previously shown that CCL2 stimulated the migration
of TSC2 LOH LAM cells,41 as did OPG. These effects on
chemotaxis may play a role in LAM cell metastasis. LAM is
a sex-speciﬁc disease in which estrogen appears to play
a role in its progression and metastasis.60 Interestingly, it
has been shown that 17b-estradiol increases both OPG and
CCL2 production in human dendritic cells.61
Patients with LAM may have secondary clinical mani-
festations, such as osteoporosis and elevated exercise-
induced pulmonary artery pressures.62,63 Of LAM patients,
70% had abnormal bone mineral densities, and the bone
mineral density correlated with severity of lung disease and
age.62 We did not ﬁnd a correlation between serum levels of
OPG and bone mineral density in LAM patients (data not
shown), similar to the ﬁndings in a healthy adult pop-
ulation.64 Another study,12 however, found both signiﬁ-
cantly higher levels of OPG in the serum of postmenopausal
women with osteoporosis than in matched normal controls
and a correlation of OPG concentrations and bone mineral
density in the postmenopausal women with osteoporosis.
High levels of serum OPG in women with osteoporosis may
be a compensative response to bone loss, as opposed to
being a cause of osteoporosis.12 It is also possible that OPG
in the serum comes from many different sources, and may
not truly reﬂect the microenvironment of the bone.64
LAM patients also experience higher than normal
exercise-induced pulmonary artery pressures.63 More than
half of the patients tested showed an increase in pulmonary
artery pressures with moderate physical activity, suggesting
that the activities of daily living may lead to pulmonary
hypertension.63 Pulmonary vascular lesions of patients with
idiopathic pulmonary artery hypertension were reactive with
anti-OPG antibodies in the concentric and plexiform lesions
of the remodeled pulmonary arteries.14 Serum OPG levels
from patients with idiopathic pulmonary artery hypertension
were higher than those of controls, and OPG induced
pulmonary artery smooth muscle cell proliferation and
migration.14 It is possible that high serum levels of OPG
play a role in pulmonary artery hypertension in LAM by
affecting non-LAM cells, such as pulmonary artery smooth
muscle cells.
Although sources of OPG include osteoblasts, immune-
competent cells (T cells, B cells, and monocytic cells),948ﬁbroblasts, smooth muscle cells, and endothelial cells,65
endothelial cells and vascular smooth muscle cells may be
the major contributors of OPG in serum.18 Both endothelial
cells andHMB45-positive LAMcells in lung tissue expressed
OPG. In one study,38 approximately 40% of LAM cells in
LAM lung tissue reacted with HMB45, a mouse monoclonal
antibody reactive to gp100.35 LAMcells that contained gp100
were primarily the larger, more differentiated, epithelioid
cells, not the small, proliferative, spindle-shaped cells. It was
reported that the extent of cellular differentiation inﬂuenced
the level of OPG expression in smooth muscle cells,13 with
highly differentiated cells producing the most OPG. These
ﬁndings are consistent with HMB45-expressing cells pro-
ducing OPG, because these cells are more highly differenti-
ated than the noneHMB45-expressing spindle-shaped cells.
Non-LAM cells may also be inﬂuenced by LAM cells to
express OPG. Direct contact with breast cancer cells stim-
ulated endothelial cells to produce OPG,66 with potential
effects on tumor angiogenesis. We show that both endo-
thelial cells and LAM cells produce OPG in LAM lung; it is
possible that LAM cells in lung, such as breast cancer cells,
increase OPG expression by endothelial cells. Because the
LAM nodule appears to produce OPG locally, the micro-
environment of the nodule may play a role in LAM cell
proliferation and dissemination. Similarly, a high local
concentration of OPG produced by non-LAM cells may
stimulate migration of LAM cells to this region. Therefore,
the microenvironment could be involved in a positive
feedback mechanism.41
In conclusion, LAM cells express both OPG and receptors
that bindOPG, includingRANKL, syndecan-1, and syndecan-
2. OPG stimulates proliferation of LAM cell cultures and
speciﬁcally induces migration of TSC2 LOH LAM cells.
Patients with LAM have signiﬁcantly higher serum levels of
OPG than healthy volunteers. These data suggest that OPG
plays a role in LAM pathogenesis and progression, acting as
both a paracrine and an autocrine factor.Acknowledgments
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